DE69304895D1 - Elimination of multi-drug resistance by tetraarylethylenes - Google Patents

Elimination of multi-drug resistance by tetraarylethylenes

Info

Publication number
DE69304895D1
DE69304895D1 DE69304895T DE69304895T DE69304895D1 DE 69304895 D1 DE69304895 D1 DE 69304895D1 DE 69304895 T DE69304895 T DE 69304895T DE 69304895 T DE69304895 T DE 69304895T DE 69304895 D1 DE69304895 D1 DE 69304895D1
Authority
DE
Germany
Prior art keywords
tetraarylethylenes
drug resistance
elimination
certain
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69304895T
Other languages
German (de)
Other versions
DE69304895T2 (en
Inventor
Sai Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69304895D1 publication Critical patent/DE69304895D1/en
Publication of DE69304895T2 publication Critical patent/DE69304895T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

Certain tetraarylethylenes reverse drug resistance in multi-drug resistant tumors. These compounds apparently function by inhibiting a p-glycoprotein pump which becomes activated in late stage tumor development and which is inherently present in tumors from certain origins.
DE69304895T 1992-02-06 1993-01-11 Elimination of multi-drug resistance by tetraarylethylenes Expired - Fee Related DE69304895T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83254192A 1992-02-06 1992-02-06
PCT/US1993/000190 WO1993015733A1 (en) 1992-02-06 1993-01-11 Reversal of multi-drug resistance by tetraarylethylenes

Publications (2)

Publication Number Publication Date
DE69304895D1 true DE69304895D1 (en) 1996-10-24
DE69304895T2 DE69304895T2 (en) 1997-02-06

Family

ID=25261952

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69304895T Expired - Fee Related DE69304895T2 (en) 1992-02-06 1993-01-11 Elimination of multi-drug resistance by tetraarylethylenes

Country Status (19)

Country Link
US (2) US5523304A (en)
EP (1) EP0624090B1 (en)
JP (1) JPH07503728A (en)
KR (1) KR950700061A (en)
AT (1) ATE142879T1 (en)
AU (1) AU668910B2 (en)
CA (1) CA2129143C (en)
DE (1) DE69304895T2 (en)
DK (1) DK0624090T3 (en)
ES (1) ES2094525T3 (en)
GR (1) GR3021811T3 (en)
HU (1) HUT75163A (en)
IL (1) IL104599A (en)
MX (1) MX9300578A (en)
NO (1) NO942918L (en)
NZ (1) NZ246818A (en)
TW (1) TW226330B (en)
WO (1) WO1993015733A1 (en)
ZA (1) ZA93690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006604A2 (en) 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
AU3486297A (en) * 1996-06-17 1998-01-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
AU6366000A (en) * 1999-07-23 2001-02-13 Colorado State University Research Foundation Multidrug resistance pump inhibitors and uses thereof
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
FR2906533B1 (en) * 2006-09-28 2013-02-22 Pf Medicament METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED THEREBY AND USES THEREOF
CN111909114A (en) * 2015-06-24 2020-11-10 香港科技大学 AIE luminophores for visualization and treatment of cancer
US10729669B2 (en) 2015-07-28 2020-08-04 University Of Iowa Research Foundation Compositions and methods for treating cancer
US9980951B2 (en) * 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
WO2017223565A1 (en) 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
US5182293A (en) * 1989-11-13 1993-01-26 Merrell Dow Pharmaceuticals Inc. Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones

Also Published As

Publication number Publication date
DK0624090T3 (en) 1996-11-11
NO942918D0 (en) 1994-08-05
JPH07503728A (en) 1995-04-20
AU668910B2 (en) 1996-05-23
WO1993015733A1 (en) 1993-08-19
TW226330B (en) 1994-07-11
GR3021811T3 (en) 1997-02-28
HU9402284D0 (en) 1994-10-28
KR950700061A (en) 1995-01-16
US5523304A (en) 1996-06-04
IL104599A0 (en) 1993-06-10
CA2129143C (en) 1997-05-06
HUT75163A (en) 1997-04-28
US5665780A (en) 1997-09-09
AU3440893A (en) 1993-09-03
EP0624090B1 (en) 1996-09-18
ES2094525T3 (en) 1997-01-16
ZA93690B (en) 1993-09-06
MX9300578A (en) 1993-08-01
DE69304895T2 (en) 1997-02-06
NZ246818A (en) 1997-07-27
EP0624090A1 (en) 1994-11-17
CA2129143A1 (en) 1993-08-19
ATE142879T1 (en) 1996-10-15
IL104599A (en) 1997-01-10
NO942918L (en) 1994-08-05

Similar Documents

Publication Publication Date Title
DE69304895D1 (en) Elimination of multi-drug resistance by tetraarylethylenes
ITTO920976A1 (en) BIMODAL EMULSION AND RELATED METHOD OF PREPARATION.
DE69003899D1 (en) Partial oxidation of sewage sludge.
DE69433406D1 (en) ANTIBODIES AGAINST CD40
BR9607171A (en) Monoclonal anti-cd6 antibodies and their uses
IS2606B (en) Tumor associated with tumor necrosis factor
ZA923602B (en) Inhibitors of cathepsin g and elastase for preventing connective tissue degradation
DE69003951D1 (en) MANUFACTURE OF MULTILAYER FILMS BY SPUTTERING.
DE3585728D1 (en) COMPOSITIONS OF UNSATURATED POLYESTER RESIN.
ATE256183T1 (en) NEW PROTEINS FROM PARASITIC WORMS
CA2152794A1 (en) Diarylalkyl Piperidines Useful as Multi-Drug Resistant Tumor Agents
DE59106038D1 (en) Explosive combustion reactor.
DE69111277D1 (en) Accelerating setting of cement compositions in oil wells.
DE69200861D1 (en) Concentration of tert-butyl hydroperoxide.
ES2106183T3 (en) ANTI-POISON SERUM.
DE69019123D1 (en) Impact-resistant and hydrolysis-resistant mixtures of polycarbonates and polyesters.
DE68901491D1 (en) METHOD TO PREVENT THE DISCOLORATION OF EMULSIONS AND EMULSION COMPOSITION RESISTANT TO DISCOLORATION.
DE69605624D1 (en) Sensitization of silver halide emulsions with precious metal complexes
Miller Prisoner of Hope
DE68910343D1 (en) Purification of tertiary butanol.
ATE155686T1 (en) INHIBITION OF METASTASIS IN CANCER PATIENTS WITH PYRIDYLOXAZOLE-2-ONES
DE68920675D1 (en) Graft copolymers, effective as additives for unsaturated polyester resins.
DE3887874D1 (en) Manufacture of customized integrated circuits.
MC2360A1 (en) New mixed double-stranded epoxides: synthesis, reactivity and applications

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee